2.2.0.25truefalse40204 - Disclosure - ALLIANCES AND COLLABORATIONS (Otsuka) (Details)truefalseIn Millions, unless otherwise specifiedfalse1falsefalseUSDfalsefalse10/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Duration_10_1_2010_To_12_31_2010http://www.sec.gov/CIK0000014272duration2010-10-01T00:00:002010-12-31T00:00:00Unit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit12Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0Unit15Standardhttp://www.xbrl.org/2003/instancesharesxbrli0Unit13Standardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$2falsefalseUSDfalsefalse7/1/2010 - 9/30/2010
USD ($)
USD ($) / shares
$Duration_7_1_2010_To_9_30_2010http://www.sec.gov/CIK0000014272duration2010-07-01T00:00:002010-09-30T00:00:00Unit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit12Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$3falsefalseUSDfalsefalse4/1/2010 - 6/30/2010
USD ($)
USD ($) / shares
$Duration_4_1_2010_To_6_30_2010http://www.sec.gov/CIK0000014272duration2010-04-01T00:00:002010-06-30T00:00:00Unit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit12Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$4falsefalseUSDfalsefalse1/1/2010 - 3/31/2010
USD ($) / shares
USD ($)
$Duration_1_1_2010_To_3_31_2010http://www.sec.gov/CIK0000014272duration2010-01-01T00:00:002010-03-31T00:00:00Unit12Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0Unit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit15Standardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$5falsefalseUSDfalsefalse10/1/2009 - 12/31/2009
USD ($)
USD ($) / shares
$Duration_10_1_2009_To_12_31_2009http://www.sec.gov/CIK0000014272duration2009-10-01T00:00:002009-12-31T00:00:00Unit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit12Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0Unit15Standardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$6falsefalseUSDfalsefalse7/1/2009 - 9/30/2009
USD ($)
USD ($) / shares
$Duration_7_1_2009_To_9_30_2009http://www.sec.gov/CIK0000014272duration2009-07-01T00:00:002009-09-30T00:00:00Unit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit12Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$7falsefalseUSDfalsefalse4/1/2009 - 6/30/2009
USD ($)
USD ($) / shares
$Duration_4_1_2009_To_6_30_2009http://www.sec.gov/CIK0000014272duration2009-04-01T00:00:002009-06-30T00:00:00Unit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit12Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$8falsefalseUSDfalsefalse1/1/2009 - 3/31/2009
USD ($)
USD ($) / shares
$Duration_1_1_2009_To_3_31_2009http://www.sec.gov/CIK0000014272duration2009-01-01T00:00:002009-03-31T00:00:00Unit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit12Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0Unit15Standardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$9falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Duration_1_1_2010_To_12_31_2010http://www.sec.gov/CIK0000014272duration2010-01-01T00:00:002010-12-31T00:00:00Unit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit13Standardhttp://www.xbrl.org/2003/instancepurexbrli0Unit12Divide<
MeasureSchema>http://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0Unit15Standardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$10falsefalseUSDfalsefalse1/1/2009 - 12/31/2009
USD ($)
USD ($) / shares
$Duration_1_1_2009_To_12_31_2009http://www.sec.gov/CIK0000014272duration2009-01-01T00:00:002009-12-31T00:00:00Unit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit15Standardhttp://www.xbrl.org/2003/instancesharesxbrli0Unit12Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0Unit13Standardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$11falsefalseUSDfalsefalse1/1/2008 - 12/31/2008
USD ($)
USD ($) / shares
$Duration_1_1_2008_To_12_31_20083http://www.sec.gov/CIK0000014272duration2008-01-01T00:00:002008-12-31T00:00:00Unit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit15Standardhttp://www.xbrl.org/2003/instancesharesxbrli0Unit13Standardhttp://www.xbrl.org/2003/instancepurexbrli0Unit12Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$12falsefalseUSDfalsefalse12/31/2007
USD ($)
$As_Of_12_31_2007http://www.sec.gov/CIK0000014272instant2007-12-31T00:00:000001-01-01T00:00:00Unit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit15Standardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$13falsefalsetruefalse{invest_InvestmentAxis} : 2010 - 2012 [Member]
{us-gaap_StatementScenarioAxis} : 0 to $400 Million [Member]
{us-gaap_BusinessAcquisitionAxis} : SPRYCEL and IXEMPRA in the Oncology Territory [Member]
1/1/2010 - 12/31/2010
Duration_1_1_2010_To_12_31_201033http://www.sec.gov/CIK0000014272duration2010-01-01T00:00:002010-12-31T00:00:00falsefalse2010 - 2012 [Member]invest_InvestmentAxisxbrldihttp://xbrl.org/2006/xbrldibmy_TwoThousandTenToTwoThousandTwelveMemberinvest_InvestmentAxisexplicitMemberfalsefalse0 to $400 Million [Member]us-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldibmy_ZeroToFourHundredMillionMemberus-gaap_StatementScenarioAxisexplicitMemberfalsefalseSPRYCEL and IXEMPRA in the Oncology Territory [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_SprycelAndIxempraInOncologyTerritoryMemberus-gaap_BusinessAcquisitionAxisexplicitMemberUnit13Standardhttp://www.xbrl.org/2003/instancepurexbrli014falsefalsetruefalse{invest_InvestmentAxis} : 2010 - 2012 [Member]
{us-gaap_StatementScenarioAxis} : $400 Million to $600 Million [Member]
{us-gaap_BusinessAcquisitionAxis} : SPRYCEL and IXEMPRA in the Oncology Territory [Member]
1/1/2010 - 12/31/2010
Duration_1_1_2010_To_12_31_201023http://www.sec.gov/CIK0000014272duration2010-01-01T00:00:002010-12-31T00:00:00falsefalse2010 - 2012 [Member]invest_InvestmentAxisxbrldihttp://xbrl.org/2006/xbrldibmy_TwoThousandTenToTwoThousandTwelveMemberinvest_InvestmentAxisexplicitMemberfalsefalse$400 Million to $600 Million [Member]us-gaap_StatementSce
narioAxisxbrldihttp://xbrl.org/2006/xbrldibmy_FourHundredToSixHundredMillionMemberus-gaap_StatementScenarioAxisexplicitMemberfalsefalseSPRYCEL and IXEMPRA in the Oncology Territory [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_SprycelAndIxempraInOncologyTerritoryMemberus-gaap_BusinessAcquisitionAxisexplicitMemberUnit13Standardhttp://www.xbrl.org/2003/instancepurexbrli
015falsefalsetruefalse{invest_InvestmentAxis} : 2010 - 2012 [Member]
{us-gaap_StatementScenarioAxis} : $600 Million to $800 Million [Member]
{us-gaap_BusinessAcquisitionAxis} : SPRYCEL and IXEMPRA in the Oncology Territory [Member]
1/1/2010 - 12/31/2010
Duration_1_1_2010_To_12_31_201032http://www.sec.gov/CIK0000014272duration2010-01-01T00:00:002010-12-31T00:00:00falsefalse2010 - 2012 [Member]invest_InvestmentAxisxbrldihttp://xbrl.org/2006/xbrldibmy_TwoThousandTenToTwoThousandTwelveMemberinvest_InvestmentAxisexplicitMemberfalsefalse$600 Million to $800 Million [Member]us-gaap_StatementSce
narioAxisxbrldihttp://xbrl.org/2006/xbrldibmy_SixHundredToEightHundredMillionMemberus-gaap_StatementScenarioAxisexplicitMemberfalsefalseSPRYCEL and IXEMPRA in the Oncology Territory [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_SprycelAndIxempraInOncologyTerritoryMemberus-gaap_BusinessAcquisitionAxisexplicitMemberUnit13Standardhttp://www.xbrl.org/2003/instancepurexbrl
i016falsefalsetruefalse{invest_InvestmentAxis} : 2010 - 2012 [Member]
{us-gaap_StatementScenarioAxis} : $800 Million to $1.0 Billion [Member]
{us-gaap_BusinessAcquisitionAxis} : SPRYCEL and IXEMPRA in the Oncology Territory [Member]
1/1/2010 - 12/31/2010
Duration_1_1_2010_To_12_31_201022http://www.sec.gov/CIK0000014272duration2010-01-01T00:00:002010-12-31T00:00:00falsefalse2010 - 2012 [Member]invest_InvestmentAxisxbrldihttp://xbrl.org/2006/xbrldibmy_TwoThousandTenToTwoThousandTwelveMemberinvest_InvestmentAxisexplicitMemberfalsefalse$800 Million to $1.0 Billion [Member]us-gaap_StatementSce
narioAxisxbrldihttp://xbrl.org/2006/xbrldibmy_EightHundredMillionToOneBillionMemberus-gaap_StatementScenarioAxisexplicitMemberfalsefalseSPRYCEL and IXEMPRA in the Oncology Territory [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_SprycelAndIxempraInOncologyTerritoryMemberus-gaap_BusinessAcquisitionAxisexplicitMemberUnit13Standardhttp://www.xbrl.org/2003/instancepurexbrl
i017falsefalsetruefalse{invest_InvestmentAxis} : 2010 - 2012 [Member]
{us-gaap_StatementScenarioAxis} : In Excess of $1.0 Billion [Member]
{us-gaap_BusinessAcquisitionAxis} : SPRYCEL and IXEMPRA in the Oncology Territory [Member]
1/1/2010 - 12/31/2010
Duration_1_1_2010_To_12_31_201024http://www.sec.gov/CIK0000014272duration2010-01-01T00:00:002010-12-31T00:00:00falsefalse2010 - 2012 [Member]invest_InvestmentAxisxbrldihttp://xbrl.org/2006/xbrldibmy_TwoThousandTenToTwoThousandTwelveMemberinvest_InvestmentAxisexplicitMemberfalsefalseIn Excess of $1.0 Billion [Member]us-gaap_StatementScenar
ioAxisxbrldihttp://xbrl.org/2006/xbrldibmy_InExcessOfOneBillionMemberus-gaap_StatementScenarioAxisexplicitMemberfalsefalseSPRYCEL and IXEMPRA in the Oncology Territory [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_SprycelAndIxempraInOncologyTerritoryMemberus-gaap_BusinessAcquisitionAxisexplicitMemberUnit13Standardhttp://www.xbrl.org/2003/instancepurexbrli018falsefalsetruefalse{invest_InvestmentAxis} : 2013 - 2020 [Member]
{us-gaap_StatementScenarioAxis} : 0 to $400 Million [Member]
{us-gaap_BusinessAcquisitionAxis} : SPRYCEL and IXEMPRA in the Oncology Territory [Member]
1/1/2010 - 12/31/2010
Duration_1_1_2010_To_12_31_2010222http://www.sec.gov/CIK0000014272duration2010-01-01T00:00:002010-12-31T00:00:00falsefalse2013 - 2020 [Member]invest_InvestmentAxisxbrldihttp://xbrl.org/2006/xbrldibmy_TwoThousandThirteenToTwoThousandTwentyMemberinvest_InvestmentAxisexplicitMemberfalsefalse0 to $400 Million [Member]us-gaap_StatementScenario
Axisxbrldihttp://xbrl.org/2006/xbrldibmy_ZeroToFourHundredMillionMemberus-gaap_StatementScenarioAxisexplicitMemberfalsefalseSPRYCEL and IXEMPRA in the Oncology Territory [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_SprycelAndIxempraInOncologyTerritoryMemberus-gaap_BusinessAcquisitionAxisexplicitMemberUnit13Standardhttp://www.xbrl.org/2003/instancepurexbrli019falsefalsetruefalse{invest_InvestmentAxis} : 2013 - 2020 [Member]
{us-gaap_StatementScenarioAxis} : $400 Million to $600 Million [Member]
{us-gaap_BusinessAcquisitionAxis} : SPRYCEL and IXEMPRA in the Oncology Territory [Member]
1/1/2010 - 12/31/2010
Duration_1_1_2010_To_12_31_201019http://www.sec.gov/CIK0000014272duration2010-01-01T00:00:002010-12-31T00:00:00falsefalse2013 - 2020 [Member]invest_InvestmentAxisxbrldihttp://xbrl.org/2006/xbrldibmy_TwoThousandThirteenToTwoThousandTwentyMemberinvest_InvestmentAxisexplicitMemberfalsefalse$400 Million to $600 Million [Member]us-gaap_Stateme
ntScenarioAxisxbrldihttp://xbrl.org/2006/xbrldibmy_FourHundredToSixHundredMillionMemberus-gaap_StatementScenarioAxisexplicitMemberfalsefalseSPRYCEL and IXEMPRA in the Oncology Territory [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_SprycelAndIxempraInOncologyTerritoryMemberus-gaap_BusinessAcquisitionAxisexplicitMemberUnit13Standardhttp://www.xbrl.org/2003/instancepure
xbrli020falsefalsetruefalse{invest_InvestmentAxis} : 2013 - 2020 [Member]
{us-gaap_StatementScenarioAxis} : $600 Million to $800 Million [Member]
{us-gaap_BusinessAcquisitionAxis} : SPRYCEL and IXEMPRA in the Oncology Territory [Member]
1/1/2010 - 12/31/2010
Duration_1_1_2010_To_12_31_201021http://www.sec.gov/CIK0000014272duration2010-01-01T00:00:002010-12-31T00:00:00falsefalse2013 - 2020 [Member]invest_InvestmentAxisxbrldihttp://xbrl.org/2006/xbrldibmy_TwoThousandThirteenToTwoThousandTwentyMemberinvest_InvestmentAxisexplicitMemberfalsefalse$600 Million to $800 Million [Member]us-gaap_Stateme
ntScenarioAxisxbrldihttp://xbrl.org/2006/xbrldibmy_SixHundredToEightHundredMillionMemberus-gaap_StatementScenarioAxisexplicitMemberfalsefalseSPRYCEL and IXEMPRA in the Oncology Territory [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_SprycelAndIxempraInOncologyTerritoryMemberus-gaap_BusinessAcquisitionAxisexplicitMemberUnit13Standardhttp://www.xbrl.org/2003/instancepurexbrli021falsefalsetruefalse{invest_InvestmentAxis} : 2013 - 2020 [Member]
{us-gaap_StatementScenarioAxis} : $800 Million to $1.0 Billion [Member]
{us-gaap_BusinessAcquisitionAxis} : SPRYCEL and IXEMPRA in the Oncology Territory [Member]
1/1/2010 - 12/31/2010
Duration_1_1_2010_To_12_31_201042http://www.sec.gov/CIK0000014272duration2010-01-01T00:00:002010-12-31T00:00:00falsefalse2013 - 2020 [Member]invest_InvestmentAxisxbrldihttp://xbrl.org/2006/xbrldibmy_TwoThousandThirteenToTwoThousandTwentyMemberinvest_InvestmentAxisexplicitMemberfalsefalse$800 Million to $1.0 Billion [Member]us-gaap_Stateme
ntScenarioAxisxbrldihttp://xbrl.org/2006/xbrldibmy_EightHundredMillionToOneBillionMemberus-gaap_StatementScenarioAxisexplicitMemberfalsefalseSPRYCEL and IXEMPRA in the Oncology Territory [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_SprycelAndIxempraInOncologyTerritoryMemberus-gaap_BusinessAcquisitionAxisexplicitMemberUnit13Standardhttp://www.xbrl.org/2003/instancepurexbrli022falsefalsetruefalse{invest_InvestmentAxis} : 2013 - 2020 [Member]
{us-gaap_StatementScenarioAxis} : In Excess of $1.0 Billion [Member]
{us-gaap_BusinessAcquisitionAxis} : SPRYCEL and IXEMPRA in the Oncology Territory [Member]
1/1/2010 - 12/31/2010
Duration_1_1_2010_To_12_31_201020http://www.sec.gov/CIK0000014272duration2010-01-01T00:00:002010-12-31T00:00:00falsefalse2013 - 2020 [Member]invest_InvestmentAxisxbrldihttp://xbrl.org/2006/xbrldibmy_TwoThousandThirteenToTwoThousandTwentyMemberinvest_InvestmentAxisexplicitMemberfalsefalseIn Excess of $1.0 Billion [Member]us-gaap_StatementS
cenarioAxisxbrldihttp://xbrl.org/2006/xbrldibmy_InExcessOfOneBillionMemberus-gaap_StatementScenarioAxisexplicitMemberfalsefalseSPRYCEL and IXEMPRA in the Oncology Territory [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_SprycelAndIxempraInOncologyTerritoryMemberus-gaap_BusinessAcquisitionAxisexplicitMemberUnit13Standardhttp://www.xbrl.org/2003/instancepurexbrli023falsefalseUSDtruefalse{invest_InvestmentAxis} : Milestone Payments [Member]
{us-gaap_BusinessAcquisitionAxis} : Otsuka [Member]
12/31/2010
USD ($)
$As_Of_12_31_201019http://www.sec.gov/CIK0000014272instant2010-12-31T00:00:000001-01-01T00:00:00falsefalseMilestone Payments [Member]invest_InvestmentAxisxbrldihttp://xbrl.org/2006/xbrldibmy_MilestonePaymentsMemberinvest_InvestmentAxisexplicitMemberfalsefalseOtsuka [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_OtsukaMemberus-gaap_BusinessAcquisitionAxisexplicitMemberUnit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$24falsefalseUSDtruefalse{invest_InvestmentAxis} : Milestone Payments [Member]
{us-gaap_BusinessAcquisitionAxis} : Otsuka [Member]
12/31/2009
USD ($)
$As_Of_12_31_20097248http://www.sec.gov/CIK0000014272instant2009-12-31T00:00:000001-01-01T00:00:00falsefalseMilestone Payments [Member]invest_InvestmentAxisxbrldihttp://xbrl.org/2006/xbrldibmy_MilestonePaymentsMemberinvest_InvestmentAxisexplicitMemberfalsefalseOtsuka [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_OtsukaMemberus-gaap_BusinessAcquisitionAxisexplicitMemberUnit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$25falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : Otsuka [Member]
{us-gaap_StatementScenarioAxis} : Extension Payment [Member]
{invest_InvestmentAxis} : ABILIFY* [Member]
12/31/2010
USD ($)
$As_Of_12_31_20103172http://www.sec.gov/CIK0000014272instant2010-12-31T00:00:000001-01-01T00:00:00falsefalseOtsuka [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_OtsukaMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseExtension Payment [Member]us-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldibmy_ExtensionPaymentMemberus-gaap_StatementScenarioAxisexplicitMemberfalsefalseABILIFY* [Member]invest_InvestmentAxisxbrldihttp://xbrl.org/2006/xbrldibmy_AbilifyMemberinvest_InvestmentAxisexplicitMemberUnit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$26falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : Otsuka [Member]
{us-gaap_StatementScenarioAxis} : Extension Payment [Member]
{invest_InvestmentAxis} : ABILIFY* [Member]
12/31/2009
USD ($)
$As_Of_12_31_20097251http://www.sec.gov/CIK0000014272instant2009-12-31T00:00:000001-01-01T00:00:00falsefalseOtsuka [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_OtsukaMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseExtension Payment [Member]us-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldibmy_ExtensionPaymentMemberus-gaap_StatementScenarioAxisexplicitMemberfalsefalseABILIFY* [Member]invest_InvestmentAxisxbrldihttp://xbrl.org/2006/xbrldibmy_AbilifyMemberinvest_InvestmentAxisexplicitMemberUnit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$27falsefalsetruefalse{us-gaap_BusinessAcquisitionAxis} : Otsuka [Member]
{invest_InvestmentAxis} : ABILIFY* [Member]
1/1/2012 - 12/31/2012
Duration_1_1_2012_To_12_31_2012http://www.sec.gov/CIK0000014272duration2012-01-01T00:00:002012-12-31T00:00:00falsefalseOtsuka [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_OtsukaMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseABILIFY* [Member]invest_InvestmentAxisxbrldihttp://xbrl.org/2006/xbrldibmy_AbilifyMemberinvest_InvestmentAxisexplicitMemberUnit13Standardhttp://www.xbrl.org/2003/instancepurexbrli028falsefalsetruefalse{us-gaap_BusinessAcquisitionAxis} : Otsuka [M
ember]
{invest_InvestmentAxis} : ABILIFY* [Member]
1/1/2011 - 12/31/2011
Duration_1_1_2011_To_12_31_2011http://www.sec.gov/CIK0000014272duration2011-01-01T00:00:002011-12-31T00:00:00falsefalseOtsuka [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_OtsukaMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseABILIFY* [Member]invest_InvestmentAxisxbrldihttp://xbrl.org/2006/xbrldibmy_AbilifyMemberinvest_InvestmentAxisexplicitMemberUnit13Standardhttp://www.xbrl.org/2003/instancepurexbrli029falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionA
xis} : Otsuka [Member]
{invest_InvestmentAxis} : ABILIFY* [Member]
1/1/2010 - 12/31/2010
USD ($)
$Duration_1_1_2010_To_12_31_2010923http://www.sec.gov/CIK0000014272duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseOtsuka [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_OtsukaMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseABILIFY* [Member]invest_InvestmentAxisxbrldihttp://xbrl.org/2006/xbrldibmy_AbilifyMemberinvest_InvestmentAxisexplicitMemberUnit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit13Standardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$30falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : Otsuka [Member]
{invest_InvestmentAxis} : ABILIFY* [Member]
1/1/2009 - 12/31/2009
USD ($)
$Duration_1_1_2009_To_12_31_20092223http://www.sec.gov/CIK0000014272duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseOtsuka [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_OtsukaMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseABILIFY* [Member]invest_InvestmentAxis<
Namespace>xbrldihttp://xbrl.org/2006/xbrldibmy_AbilifyMemberinvest_InvestmentAxisexplicitMemberUnit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$31falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : Otsuka [Member]
{invest_InvestmentAxis} : ABILIFY* [Member]
1/1/2008 - 12/31/2008
USD ($)
$Duration_1_1_2008_To_12_31_20083238http://www.sec.gov/CIK0000014272duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseOtsuka [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_OtsukaMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseABILIFY* [Member]invest_InvestmentAxis<
Namespace>xbrldihttp://xbrl.org/2006/xbrldibmy_AbilifyMemberinvest_InvestmentAxisexplicitMemberUnit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$32falsefalsetruefals
e{us-gaap_StatementScenarioAxis} : 0 to $2.7 Billion [Member]
{invest_InvestmentAxis} : ABILIFY* [Member]
1/1/2013 - 12/31/2013
Duration_1_1_2013_To_12_31_201324http://www.sec.gov/CIK0000014272duration2013-01-01T00:00:002013-12-31T00:00:00falsefalse0 to $2.7 Billion [Member]us-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldibmy_ZeroToTwoPointSevenBillionMemberus-gaap_StatementScenarioAxisexplicitMemberfalsefalseABILIFY* [Member]invest_InvestmentAxisxbrldihttp://xbrl.org/2006/xbrldibmy_AbilifyMemberinvest_InvestmentAxisexplicitMemberUnit13Standardhttp://www.xbrl.org/2003/instancepurexbrli033falsefalsetruefalse{us-g
aap_StatementScenarioAxis} : $2.7 Billion to $3.2 Billion [Member]
{invest_InvestmentAxis} : ABILIFY* [Member]
1/1/2013 - 12/31/2013
Duration_1_1_2013_To_12_31_201323http://www.sec.gov/CIK0000014272duration2013-01-01T00:00:002013-12-31T00:00:00falsefalse$2.7 Billion to $3.2 Billion [Member]us-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldibmy_TwoPointSevenToThreePointTwoBillionMemberus-gaap_StatementScenarioAxisexplicitMemberfalsefalseABILIFY* [Member]inves
t_InvestmentAxisxbrldihttp://xbrl.org/2006/xbrldibmy_AbilifyMemberinvest_InvestmentAxisexplicitMemberUnit13Standardhttp://www.xbrl.org/2003/instancepurexbrli034falsefalsetruefalse{us-gaap_StatementScenarioAxis} : $3.2 Billion to $3.7 Billion [Member]
{invest_InvestmentAxis} : ABILIFY* [Member]
1/1/2013 - 12/31/2013
Duration_1_1_2013_To_12_31_201322http://www.sec.gov/CIK0000014272duration2013-01-01T00:00:002013-12-31T00:00:00falsefalse$3.2 Billion to $3.7 Billion [Member]us-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldibmy_ThreePointTwoToThreePointSevenBillionMemberus-gaap_StatementScenarioAxisexplicitMemberfalsefalseABILIFY* [Member]inv
est_InvestmentAxisxbrldihttp://xbrl.org/2006/xbrldibmy_AbilifyMemberinvest_InvestmentAxisexplicitMemberUnit13Standardhttp://www.xbrl.org/2003/instancepurexbrli035falsefalsetruefalse<
/hasScenarios>{us-gaap_StatementScenarioAxis} : $3.7 Billion to $4.0 Billion[Member]
{invest_InvestmentAxis} : ABILIFY* [Member]
1/1/2013 - 12/31/2013
Duration_1_1_2013_To_12_31_20133http://www.sec.gov/CIK0000014272duration2013-01-01T00:00:002013-12-31T00:00:00falsefalse$3.7 Billion to $4.0 Billion[Member]us-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldibmy_ThreePointSevenToFourPointZeroBillionMemberus-gaap_StatementScenarioAxisexplicitMemberfalsefalseABILIFY* [Member]inves
t_InvestmentAxisxbrldihttp://xbrl.org/2006/xbrldibmy_AbilifyMemberinvest_InvestmentAxisexplicitMemberUnit13Standardhttp://www.xbrl.org/2003/instancepurexbrli036falsefalsetruefalse{us-gaap_StatementScenarioAxis} : $4.0 Billion to $4.2 Billion [Member]
{invest_InvestmentAxis} : ABILIFY* [Member]
1/1/2013 - 12/31/2013
Duration_1_1_2013_To_12_31_2013http://www.sec.gov/CIK0000014272duration2013-01-01T00:00:002013-12-31T00:00:00falsefalse$4.0 Billion to $4.2 Billion [Member]us-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldibmy_FourPointZeroToFourPointTwoBillionMemberus-gaap_StatementScenarioAxisexplicitMemberfalsefalseABILIFY* [Member]invest_I
nvestmentAxisxbrldihttp://xbrl.org/2006/xbrldibmy_AbilifyMemberinvest_InvestmentAxisexplicitMemberUnit13Standardhttp://www.xbrl.org/2003/instancepurexbrli037falsefalsetruefalse{us-gaap_StatementScenarioAxis} : In Excess of $4.2 Billion [Member]
{invest_InvestmentAxis} : ABILIFY* [Member]
1/1/2013 - 12/31/2013
Duration_1_1_2013_To_12_31_20132http://www.sec.gov/CIK0000014272duration2013-01-01T00:00:002013-12-31T00:00:00falsefalseIn Excess of $4.2 Billion [Member]us-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldibmy_InExcessOfFourPointTwoBillionMemberus-gaap_StatementScenarioAxisexplicitMemberfalsefalseABILIFY* [Member]invest_Investme
ntAxisxbrldihttp://xbrl.org/2006/xbrldibmy_AbilifyMemberinvest_InvestmentAxisexplicitMemberUnit13Standardhttp://www.xbrl.org/2003/instancepurexbrli038falsefalsetruefalse<
MCU>{us-gaap_BusinessAcquisitionAxis} : 2010 [Member]
{invest_InvestmentAxis} : ABILIFY* [Member]
{dei_LegalEntityAxis} : Territory Covering the U.S. [Member]
1/1/2010 - 12/31/2010
Duration_1_1_2010_To_12_31_20103322http://www.sec.gov/CIK0000014272duration2010-01-01T00:00:002010-12-31T00:00:00falsefalse2010 [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_TwoThousandAndTenMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseABILIFY* [Member]invest_InvestmentAxisxbrldihttp://xbrl.org/2006/xbrldibmy_AbilifyMemberinvest_InvestmentAxisexplicitMemberfalsefalseTerritory Covering the U.S. [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldibmy_TerritoryCoveringUSMemberdei_LegalEntityAxisexplicitMemberUnit13Standardhttp://www.xbrl.org/2003/instancepurexbrli039falsefalsetruefalse{us-gaap_BusinessAcquisitionAxis} : 2010 [Member]
{invest_InvestmentAxis} : ABILIFY* [Member]
{dei_LegalEntityAxis} : Territory Covering the U.S. [Member]
1/1/2009 - 12/31/2009
Duration_1_1_2009_To_12_31_20092226http://www.sec.gov/CIK0000014272duration2009-01-01T00:00:002009-12-31T00:00:00falsefalse2010 [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_TwoThousandAndTenMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseABILIFY* [Member]invest_InvestmentAxisxbrldihttp://xbrl.org/2006/xbrldibmy_AbilifyMemberinvest_InvestmentAxisexplicitMemberfalsefalseTerritory Covering the U.S. [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldibmy_TerritoryCoveringUSMemberdei_LegalEntityAxisexplicitMemberUnit13Standardhttp://www.xbrl.org/2003/instancepurexbrli040falsefalseUSDtruefalse{invest_InvestmentAxis} : Abilify and Oncology Products [Member]
{us-gaap_BusinessAcquisitionAxis} : Otsuka [Member]
1/1/2010 - 12/31/2010
USD ($)
$Duration_1_1_2010_To_12_31_201063http://www.sec.gov/CIK0000014272duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseAbilify and Oncology Products [Member]invest_InvestmentAxisxbrldihttp://xbrl.org/2006/xbrldibmy_AbilifyAndOncologyProductsMemberinvest_InvestmentAxisexplicitMemberfalsefalseOtsuka [Member]us-gaap_Busines
sAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_OtsukaMemberus-gaap_BusinessAcquisitionAxisexplicitMemberUnit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$41falsefalseUSDtruefalse{invest_InvestmentAxis} : Oncology Products [Member]
1/1/2010 - 12/31/2010
USD ($)
$Duration_1_1_2010_To_12_31_2010422http://www.sec.gov/CIK0000014272duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseOncology Products [Member]invest_InvestmentAxisxbrldihttp://xbrl.org/2006/xbrldibmy_OncologyProductsMemberinvest_InvestmentAxisexplicitMemberUnit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$42falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : Otsuka [Member]
1/1/2010 - 12/31/2010
USD ($)
$Duration_1_1_2010_To_12_31_2010744http://www.sec.gov/CIK0000014272duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseOtsuka [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_OtsukaMemberus-gaap_BusinessAcquisitionAxisexplicitMemberUnit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$43falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : Otsuka [Member]
1/1/2009 - 12/31/2009
USD ($)
$Duration_1_1_2009_To_12_31_20092240http://www.sec.gov/CIK0000014272duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseOtsuka [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_OtsukaMemberus-gaap_BusinessAcquisitionAxisexplicitMemberUnit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$44falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : Otsuka [Member]
1/1/2008 - 12/31/2008
USD ($)
$Duration_1_1_2008_To_12_31_200819http://www.sec.gov/CIK0000014272duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseOtsuka [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_OtsukaMemberus-gaap_BusinessAcquisitionAxisexplicitMemberUnit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false0bmy_PercentageOfNetSalesRecognizedFromCollaborationbmyfalsenadurationThe percentage of sales within a range of total sales to be recognized pursuant to the collaboration agreement.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsetruefalse00falsefalsefalsefalsefalse2falsetruefalse00falsefalsefalsefalsefalse3falsetruefalse00falsefalsefalsefalsefalse4falsetruefalse00falsefalsefalsefalsefalse5falsetruefalse00falsefalsefalsefalsefalse6falsetruefalse00<
FootnoteIndexer />falsefalsefalsefalsefalse7falsetruefalse00falsefalsefalsefalsefalse8falsetruefalse00falsefalsefalsefalsefalse9falsetruefalse00falsefalsefalsefalsefalse10falsetruefalse00falsefalsefalsefalsefalse11falsetruefalse00falsefalsefalsefalsefalse12falsetruefalse00falsefalsefalsefalsefalse13falsetruefalse00falsefalsefalsetruefalse14falsetruefalse00falsefalsefalsetruefalse15falsetruefalse00falsefalsefalsetruefalse16falsetruefalse00falsefalsefalsetruefalse17falsetruefalse00falsefalsefalsetruefalse18falsetruefalse00falsefalsefalsetruefalse19falsetruefalse00falsefalsefalsetruefalse20falsetruefalse00falsefalsefalsetruefalse21falsetruefalse00falsefalsefalsetruefalse22falsetruefalse00falsefalsefalsetruefalse23falsetruefalse00falsefalsefalsetruefalse24falsetruefalse00falsefalsefalsetruefalse25falsetruefalse00falsefalsefalsetruefalse26falsetruefalse00falsefalsefalsetruefalse27truetruefalse0.5150.515falsefalsefalsetruefalse28truetruefalse0.5350.535falsefalsefalsetruefalse29truetruefalse0.580.58falsefalsefalsetruefalse30falsetruefalse00falsefalsefalsetruefalse31falsetruefalse00falsefalsefalsetruefalse32truetruefalse0.50.5falsefalsefalsetruefalse33truetruefalse0.20.2falsefalsefalsetruefalse34truetruefalse0.070.07falsefalsefalsetruefalse35truetruefalse0.020.02falsefalsefalsetruefalse36truetruefalse0.010.01falsefalsefalsetruefalse37truetruefalse0.20.2falsefalsefalsetruefalse38truetruefalse0.580.58falsefalsefalsetruefalse39truetruefalse0.650.65falsefalsefalsetruefalse40falsetruefalse00falsefalsefalsetruefalse41falsetruefalse00falsefalsefalsetruefalse42falsetruefalse00falsefalsefalsetruefalse43falsetruefalse00falsefalsefalsetruefalse44falsetruefalse00f
alsefalsefalsetruefalseOtherus-types:percentItemTypepureThe percentage of sales within a range of total sales to be recognized pursuant to the collaboration agreement.No authoritative reference available.falsefalse3false0bmy_CollaborationFeePercentagebmyfalsenadurationThe percentage of annual net sales of certain products paya
ble as a collaboration fee to third parties in alliances and...falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsetruefalse00falsefalsefalsefalsefalse2falsetruefalse00falsefalsefalsefalsefalse3falsetruefalse00falsefalsefalsefa
lsefalse4falsetruefalse00falsefalsefalsefalsefalse5falsetruefalse00falsefalsefalsefalsefalse6falsetruefalse00falsefalsefalsefalsefalse7falsetruefalse00falsefalsefalsefalsefalse8falsetruefalse00falsefalsefalsefalsefalse9falsetruefalse00falsefalsefalsefalsefalse10falsetruefalse00falsefalsefalsefalsefalse11falsetruefalse00falsefalsefalsefalsefalse12falsetruefalse00falsefalsefalsefalsefalse13truetruefalse0.30.3falsefalsefalsetruefalse14truetruefalse0.050.05falsefalsefalsetruefalse15truetruefalse0.030.03falsefalsefalsetruefalse16truetruefalse0.020.02falsefalsefalsetruefalse17truetruefalse0.010.01falsefalsefalsetruefalse18truetruefalse0.650.65falsefalsefalsetruefalse19truetruefalse0.120.12falsefalsefalsetruefalse20truetruefalse0.030.03falsefalsefalsetruefalse21truetruefalse0.020.02falsefalsefalsetruefalse22truetruefalse0.010.01falsefalsefalsetruefalse23falsetruefalse00falsefalsefalsetruefalse24falsetruefalse00falsefalsefalsetruefalse25falsetruefalse00falsefalsefalsetruefalse26falsetruefalse00falsefalsefalsetruefalse27falsetruefalse00falsefalsefalsetruefa
lse28falsetruefalse00falsefalsefalsetruefalse29falsetruefalse00falsefalsefalsetruefalse30falsetruefalse00falsefalsefalsetruefalse31falsetruefalse00falsefalsefalsetruefalse32falsetruefalse00falsefalsefalsetruefalse33falsetruefalse00falsefalsefalsetruefalse34falsetruefalse00falsefalsefalsetruefalse35falsetruefalse00falsefalsefalsetruefalse36falsetruefalse00falsefalsefalsetruefalse37falsetruefalse00falsefalsefalsetruefalse
38falsetruefalse00falsefalsefalsetruefalse39falsetruefalse00falsefalsefalsetruefalse40falsetruefalse00falsefalsefalsetruefalse41falsetruefalse00falsefalsefalsetruefalse42falsetruefalse00falsefalsefalsetruefalse43falsetruefalse00falsefalsefalsetruefalse44fal
setruefalse00falsefalsefalsetruefalseOtherus-types:percentItemTypepureThe percentage of annual net sales of certain products payable as a collaboration fee to third parties in alliances and collaborations.No authoritative reference available.falsefalse4false<
/IsAbstractGroupTitle>0us-gaap_SalesRevenueNetus-gaaptruecreditdurationNo definition available.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
84falsetruefalsefalsefalse10truefalsefalse1880800000018808falsetruefalsefalsefalse11truefalsefalse1771500000017715falsetruefalsefalsefalse12falsefalsefalse00falsefalsefalsefalsefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00<
/RoundedNumericAmount>falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalse24falsefalsefalse00falsefalsefalsetruefalse25falsefalsefalse00falsefalsefalsetruefalse26falsefalsefalse00falsefalsefalsetruefalse27falsefalsefalse00falsefalsefalsetruefalse28falsefalsefalse00falsefalsefalsetruefalse29truefalsefalse25650000002565falsetruefalsetruefalse30truefalsefalse25920000002592falsetruefalsetruefalse31truefalsefalse21530000002153falsetruefalsetruefalse32falsefalsefalse00falsefalsefalsetruefalse33falsefalsefalse00<
/RoundedNumericAmount>falsefalsefalsetruefalse34falsefalsefalse00falsefalsefalsetruefalse35falsefalsefalse00falsefalsefalsetruefalse36falsefalsefalse00falsefalsefalsetruefalse37falsefalsefalse00falsefalsefalsetruefalse38falsefalsefalse00falsefalsefalsetruefalse39falsefalsefalse00falsefalsefalsetruefalse40falsefalsefalse00falsefalsefalsetruefalse41falsefalsefalse00falsefalsefalsetruefalse42falsefalsefalse00falsefalsefalsetruefalse43falsefalsefalse00falsefalsefalsetruefalse44falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryTotal revenue from s
ale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 1
-Article 5
falsefalse5false0bmy_CollaborationFeesbmyfalsedebitdurationThe amount of collaboration fees recognized in cost of products sold for the period.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalse6falsefalsefalse00falsefalsefalsefalsefalse7falsefalsefalse00falsefalsefalsefalsefalse8falsefalsefalse00falsefalsefalsefalsefalse9falsefalsefalse00falsefalsefalsefalsefalse10falsefalsefalse00falsefalsefalsefalsefalse11falsefalsefalse00falsefalsefalsefalsefalse12falsefalsefalse00falsefalsefalsefalsefalse13
falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21fals
efalsefalse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalse24falsefalsefalse00falsefalsefalsetruefalse25falsefalsefalse00falsefalsefalsetruefalse26falsefalsefalse00falsefalsefalsetruefalse27falsefalsefalse00falsefalsefalsetruefalse28falsefalsefalse00falsefalsefalsetruefalse29falsefalsefalse00falsefalsefalsetruefalse30falsefalsefalse00falsefalsefalsetruefalse31falsefal
sefalse00falsefalsefalsetruefalse32falsefalsefalse00falsefalsefalsetruefalse33falsefalsefalse00falsefalsefalsetruefalse34falsefalsefalse00falsefalsefalsetruefalse35falsefalsefalse00falsefalsefalsetruefalse36falsefalsefalse00falsefalsefalsetruefalse37falsefalsefalse00falsefalsefalsetruefalse38falsefalsefalse00falsefalsefalsetruefalse39falsefalsefalse00falsefalsefalsetruefalse40falsefalsefalse00falsefalsefalsetruefalse41truefalsefalse128000000128falsefalsefalsetruefalse42falsefalsefalse00falsefalsefalsetruefalse43falsefalsefalse00falsefalsefalsetruefalse44falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrl
i:monetaryItemTypemonetaryThe amount of collaboration fees recognized in cost of products sold for the period.No authoritative reference available.falsefalse6false0bmy_ReimbursementOfOperationalExpenseFromCollaborationsbmyfalsecreditdurationThe amount of operating expenses reimbursed by the collaboration partner pursuant to the terms of the agreement.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalse6falsefalsefalse00falsefalsefalsefalsefalse7falsefalsefalse00falsefalsefalsefalsefalse8falsefalsefalse00falsefalsefalsefalsefalse9falsefalsefalse00falsefalsefalsefalsefalse10falsefalsefalse00falsefalsefalsefalsefalse11falsefalsefalse00falsefalsefalsefalsefalse12falsefalsefalse00falsefalsefalsefalsefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22falsefalsefalse00<
CurrencyCode />falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalse24falsefalsefalse00falsefalsefalsetruefalse25falsefalsefalse00falsefalsefalsetruefalse26falsefalsefalse00falsefalsefalsetruefalse27falsefalsefalse00falsefalsefalsetruefalse28falsefalsefalse00falsefalsefalsetruefalse29falsefalsefalse00falsefalsefalsetruefalse30falsefalsefalse00falsefalsefalsetruefalse31falsefalsefalse00falsefalsefalsetruefalse32falsefalsefalse00falsefalsefalsetruefalse33falsefalsefalse00falsefalsefalsetruefalse34falsefalsefalse00falsefalsefalsetruefalse35falsefalsefalse00falsefalsefalsetruefalse36falsefalsefalse00falsefalsefalsetruefalse37falsefalsefalse00falsefalsefalsetruefalse38falsefalsefalse00falsefalsefalsetruefalse39falsefalsefalse00falsefalsefalsetruefalse40truefalsefalse-101000000-101<
IsIndependantCurrency>falsefalsefalsetruefalse41falsefalsefalse00falsefalsefalsetruefalse42falsefalsefalse00falsefalsefalsetruefalse43falsefalsefalse00falsefalsefalsetruefalse44falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryThe amount of operating expenses reimbursed by the collaboration partner pursuant to the terms of the agreement.No authoritative reference available.falsefalse7false0bmy_OtherAmortizationOfDeferredCostsbmyfalsedebitdurationThe reductio
n of net sales in the period representing the allocation of an extension payment to periods expected to benefit...falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalse6falsefalsefalse00falsefalsefalsefalsefalse7falsefalsefalse00falsefalsefa
lsefalsefalse8falsefalsefalse00falsefalsefalsefalsefalse9falsefalsefalse00falsefalsefalsefalsefalse10falsefalsefalse00falsefalsefalsefalsefalse11falsefalsefalse00falsefalsefalsefalsefalse12falsefalsefalse00falsefalsefalsefalsefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalse24falsefalsefalse00falsefalsefalsetruefalse25falsefalsefalse00falsefalsefalset
ruefalse26falsefalsefalse00falsefalsefalsetruefalse27falsefalsefalse00falsefalsefalsetruefalse28falsefalsefalse00falsefalsefalsetruefalse29truefalsefalse-66000000-66falsefalsefalsetr
uefalse30truefalsefalse-49000000-49falsefalsefalsetruefalse31falsefalsefalse00falsefalsefalsetruefalse32falsefalsefalse00falsefalsefalsetruefalse33falsefalsefalse00falsefalsefalsetru
efalse34falsefalsefalse00falsefalsefalsetruefalse35falsefalsefalse00falsefalsefalsetruefalse36falsefalsefalse00falsefalsefalsetruefalse37falsefalsefalse00falsefalsefalsetruefalse38falsefalsefalse00falsefalsefalsetruefalse39falsefalsefalse00falsefalsefalsetruefalse40falsefalsefalse00falsefalsefalsetruefalse41falsefalsefalse00falsefalsefalsetruefalse42falsefalsefalse00falsefalsefalsetruefalse43falsefalsefalse00falsefalsefalsetruefalse44falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryThe reduction of net sales in the period representing the allocation of an extension payment to periods expected to benefit from such costs, such as the extension period.No authoritative reference available.falsefalse8false0us-gaap_AmortizationOfIntangibleAssetsus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalse6falsefalsefalse00falsefalsefalsefalsefalse7falsefalsefalse00falsefalsefalsefalsefalse8falsefalsefalse00falsefalsefalsefalsefalse9falsefalsefalse00falsefalsefalsefalsefalse10falsefalsefalse00falsefalsefalsefalsefalse11falsefalsefalse0<
/NumericAmount>0falsefalsefalsefalsefalse12falsefalsefalse00falsefalsefalsefalsefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalse24falsefalsefalse00falsefalsefalsetruefalse25falsefalsefalse00falsefalsefalsetruefalse26falsefalsefalse00falsefalsefalsetruefalse27falsefalsefalse00
falsefalsefalsetruefalse28falsefalsefalse00falsefalsefalsetruefalse29falsefalsefalse00falsefalsefalsetruefalse30falsefalsefalse00falsefalsefalsetruefalse31falsefalsefalse00falsefalsefalsetruefalse32falsefalsefalse00falsefalsefalsetruefalse33falsefalsefalse00falsefalsefalsetruefalse34falsefalsefalse00falsefalsefalsetruefalse35falsefalsefalse00falsefalsefalsetruefalse36falsefalsefalse00falsefalsefalsetruefalse37falsefalsefalse00falsefalsefalsetruefalse38falsefalsefalse00falsefalsefalsetruefalse39falsefalsefalse00falsefalsefalsetruefalse40falsefalsefalse00falsefalsefalsetruefalse41falsefalsefalse00falsefalsefalsetruefalse42truefalsefalse60000006falsefalsefalsetruefalse43truefalsefalse60000006falsefalsefalsetruefalse44truefalsefalse60000006falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryThe aggregate expen
se charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by (used in) operations using the indirect method.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 45
-Subparagraph a(2)
falsefalse9false0us-gaap_OtherAssetsNoncurrentus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1truefalse
false10050000001005falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5truefals
efalse907000000907falsefalsefalsefalsefalse6falsefalsefalse00falsefalsefalsefalsefalse7falsefalsefalse00falsefalsefalsefalsefalse8falsefalsefalse00falsefalsefalsefalsefalse9truefalse
false10050000001005falsefalsefalsefalsefalse10truefalsefalse907000000907falsefalsefalsefalsefalse11falsefalsefalse00falsefalsefalsefalsefalse12falsefalsefalse00falsefalsefalsefalsefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17false
falsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalse
false00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalse24falsefalsefalse00falsefalsefalsetruefalse25truefalsefalse285000000285falsefalsefalsetruefalse26truefalsefalse351000000351falsefalsefalsetruefalse27falsefalsefalse00falsefalsefalsetruefalse28falsefalsefalse00falsefalsefalsetruefalse29falsefalsefalse00falsefalsefalsetruefalse30falsefalsefalse00falsefalsefalsetruefalse31falsefalsefalse00falsefalsefalsetruefalse32falsefalsefalse00falsefalsefalsetruefalse33falsefalsefalse00falsefalsefalsetruefalse34falsefalsefalse00falsefalsefalsetruefalse35falsefalsefalse00falsefalsefalsetruefalse36falsefalsefalse00falsefalsefalsetruefalse37falsefalsefalse00falsefalsefalsetruefalse38falsefalsefalse00falsefalsefalsetruefalse39falsefalsefal
se00falsefalsefalsetruefalse40falsefalsefalse00falsefalsefalsetruefalse41falsefalsefalse00falsefalsefalsetruefalse42falsefalsefalse00falsefalsefalsetruefalse43falsefalsefalse00falsefalsefalsetruefalse44falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryAggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet due to materiality considerations. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 17
-Article 5
falsefalse10false0us-gaap_IntangibleAssetsNetExcludingGoodwillus-gaaptruedebitinstantNo definition available.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
falsefalse11510000001151falsetruefalsefalsefalse12truefalsefalse13300000001330falsetruefalsefalsefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19fa
lsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23truefalsefalse1100000011falsetruefalsetruefalse24truefalsefalse1700000017falsetruefalsetruefalse25false
falsefalse00falsefalsefalsetruefalse26falsefalsefalse00falsefalsefalsetruefalse27falsefalsefalse00falsefalsefalsetruefalse28falsefalsefalse00falsefalsefalsetruefalse29falsefalsefalse00falsefalsefalsetruefalse30falsefalsefalse00falsefalsefalsetruefalse31falsefalsefalse00falsefalsefalsetruefalse32falsefalsefalse00falsefalsefalsetruefalse33falsefalsefalse00falsefalsefalsetruefalse34falsefalsefalse00falsefalsefalsetruefalse35falsefals
efalse00falsefalsefalsetruefalse36falsefalsefalse00falsefalsefalsetruefalse37falsefalsefalse00falsefalsefalsetruefalse38falsefalsefalse00falsefalsefalsetruefalse39falsefalsefalse00falsefalsefalsetruefalse40falsefalsefalse00falsefalsefalsetruefalse41falsefalsefalse00falsefalsefalsetruefalse42falsefalsefalse00falsefalsefalsetruefalse43falsefalsefalse00falsefalsefalsetruefalse44falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrl
i:monetaryItemTypemonetarySum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 42, 45
falsefalse449ALLIANCES AND COLLABORATIONS (Otsuka) (Details) (USD $)MillionsUnKnownUnKnownUnKnowntruetrue
